Literature DB >> 11874160

Chlamydia pneumoniae and severity of asthma.

Hertzen Leena Von1, Tuula Vasankari, Kari Liippo, Eva Wahlström, Mirja Puolakkainen.   

Abstract

A substantial increase in the prevalence of asthma in the Western world during the last few decades has led to a continuous search for novel factors that might be involved in the development of the disease. We carried out a study to clarify whether there is a relationship between severity of asthma and Chlamydia pneumoniae-specific titres at the group level and whether antibodies to the 60 kDa chlamydial heat shock protein (chsp60) are associated with asthma. A total of 116 (31 men, 85 women) consecutive asthma patients from a chest clinic were recruited and divided into 3 groups according to the severity of the disease: there were 13 asthmatics with severe, 54 with moderate and 49 with mild asthma. In addition, 50 (31 men, 19 women) consecutive blood donors were enrolled to serve as a control group. Sera for the measurements of specific IgG, IgA and IgM antibodies using a microimmunofluorescence test and of chsp60 using an enzyme immunoassay were obtained upon enrolment and also 3-4 months later from the asthma patients. Severe and moderate asthma were found to be strongly associated with elevated IgA antibody levels to C. pneumoniae [odds ratio (OR) 5.58, 95% confidence interval (CI) 1.31-23.72 for severe and OR 5.65, 95% CI 2.05-15.53 for moderate asthma] in a logistic regression model. Furthermore, in women, the occurrence of elevated IgA antibody levels and the age-adjusted geometric mean titres of IgA antibodies were significantly higher among the asthmatics than the controls (p = 0.003 and 0.04, respectively). Antibodies to chsp60 occurred more frequently and in higher concentrations among the asthmatics than the controls, although the differences did not reach significance. In conclusion, severe and moderate asthma were significantly associated with elevated IgA antibody levels to C. pneumoniae suggestive of chronic infection. Antibodies to chsp60 did not prove to be a useful marker of such an infection among the asthmatics studied here.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11874160     DOI: 10.1080/00365540110077155

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  11 in total

1.  Isolation of Chlamydia pneumoniae clonal variants by a focus-forming assay.

Authors:  Jens Gieffers; Robert J Belland; William Whitmire; Scot Ouellette; Deborah Crane; Matthias Maass; Gerald I Byrne; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

Review 2.  Epidemiology of Infections and Development of Asthma.

Authors:  Jenny Resiliac; Mitchell H Grayson
Journal:  Immunol Allergy Clin North Am       Date:  2019-04-30       Impact factor: 3.479

3.  Chlamydophila pneumoniae enhances secretion of VEGF, TGF-beta and TIMP-1 from human bronchial epithelial cells under Th2 dominant microenvironment.

Authors:  Chan-Sun Park; Tae-Bum Kim; Keun Ae Moon; Yun-Jeong Bae; Hee Ran Lee; Min Kyoung Jang; Hee-Bom Moon; You Sook Cho
Journal:  Allergy Asthma Immunol Res       Date:  2009-12-30       Impact factor: 5.764

4.  Seroprevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in stable asthma and chronic obstructive pulmonary disease.

Authors:  Seoung-Ju Park; Yong-Chul Lee; Yang-Keun Rhee; Heung-Bum Lee
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

5.  Chlamydia pneumoniae Infection and Inflammatory Diseases.

Authors:  Rebecca A Porritt; Timothy R Crother
Journal:  For Immunopathol Dis Therap       Date:  2016

Review 6.  [Infections and asthma].

Authors:  G Rohde; J Rupp
Journal:  Internist (Berl)       Date:  2008-11       Impact factor: 0.743

7.  Chlamydia pneumoniae-specific IgE is prevalent in asthma and is associated with disease severity.

Authors:  David L Hahn; Allison Schure; Katir Patel; Tawanna Childs; Eduard Drizik; Wilmore Webley
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

8.  Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma.

Authors:  David L Hahn; Mary Beth Plane; Olaimatu S Mahdi; Gerald I Byrne
Journal:  PLoS Clin Trials       Date:  2006-06-30

Review 9.  Infection-mediated asthma: etiology, mechanisms and treatment options, with focus on Chlamydia pneumoniae and macrolides.

Authors:  Wilmore C Webley; David L Hahn
Journal:  Respir Res       Date:  2017-05-19

Review 10.  The role of antibiotics in asthma.

Authors:  Francesco Blasi; Sebastian L Johnston
Journal:  Int J Antimicrob Agents       Date:  2007-03-13       Impact factor: 5.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.